COVID-19: Uso de ivermectina
et al. (Preprint)
, COVID-19: Uso de ivermectina, et al. (Preprint)
Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before, relative risk RR 0.082, p=0.003.
|
risk of death, 91.8% lower, RR 0.08, p = 0.009, treatment 1 of 311 (0.3%), control 5 of 128 (3.9%), NNT 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Alonso et al., 1 Dec 2020, retrospective, Argentina, preprint, 1 author, dosage not specified.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.